Salarius Pharmaceuticals Announces Merger with Decoy Therapeutics

Introduction to SALARIUS PHARMACEUTICALS INC

Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) is a clinical-stage biopharmaceutical company headquartered in Houston, Texas. Founded in 2011, Salarius develops targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs) to address gene-expression dysregulation in solid and hematologic cancers. Its lead TPI, seclidemstat (SP-2577), is currently in Phase 1/2 trials, while the lead TPD, SP-3164, is undergoing IND-enabling studies and is expected to enter clinical trials in the second half of 2023.

Corporate Structure and Leadership

Salarius employs between 11 and 50 people and operates from the Texas Medical Center Innovation facility.
• David Arthur serves as President and Chief Executive Officer.
• Mark Rosenblum is Chief Financial Officer.
• William McVicar, Ph.D., is Chair of the Board of Directors.
The company collaborates with the MD Anderson Cancer Center and has received support from the Cancer Prevention and Research Institute of Texas (CPRIT) and the National Pediatric Cancer Foundation.

Recent Developments and News

On January 13, 2025, Salarius and Decoy Therapeutics announced a definitive merger agreement under which Decoy will merge into a wholly-owned subsidiary of Salarius, with the combined entity to be named Decoy Therapeutics. The transaction is intended to facilitate the development of Salarius’s oral small-molecule degrader SP-3164 and support the ongoing development of seclidemstat at MD Anderson.
On April 16, 2025, Massachusetts Institute of Technology Professor Robert S. Langer was appointed to Decoy’s Scientific Advisory Board, pending the completion of the merger.
Salarius filed an amended Form S-1 on June 16, 2025, updating registration details under the Securities Act of 1933. It also submitted Form 8-K reports on June 11 and June 16, 2025, disclosing material events, including leadership updates and merger-related matters.

Financial and Strategic Analysis

As of June 17, 2025, Salarius shares closed at $1.3199, reflecting an increase of 111.15% on a trading volume of 5,088,289 shares on NASDAQ. The company has not generated commercial revenues to date and relies on equity offerings, grants, and partnerships to fund its operations. Salarius received a $16.1 million award from CPRIT and in-kind support from the National Pediatric Cancer Foundation, while the Decoy merger provides access to approximately $7 million in non-dilutive funding for developing peptide conjugates.
Strategically, Salarius intends to leverage its LSD1 inhibitor platform and integrate SP-3164’s molecular glue scaffold into advanced proteolysis targeting chimeras (PROTACs). Ongoing trials of seclidemstat target Ewing sarcoma and myelodysplastic syndromes, while SP-3164's IND-enabling studies are focused on hematologic and solid tumors. Future capital raises or strategic partnerships are anticipated to support the advancement of multiple pipeline programs.

Market Position and Industry Context

Salarius operates in the oncology sector, focusing on cancers with high unmet medical needs through epigenetic therapies. Seclidemstat received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the U.S. FDA for Ewing sarcoma, which affects about 500 new patients annually in the U.S. Investigator-initiated trials at MD Anderson are exploring combinations of seclidemstat with treatments for myelodysplastic syndromes and chronic myelomonocytic leukemia, which can progress to acute myeloid leukemia (approximately 20,000 new cases in 2020). The merger with Decoy Therapeutics places the combined company in the peptide conjugate therapeutics sector, utilizing AI-enabled drug design technologies to address respiratory viruses and cancer.

tl;dr

On June 17, 2025, SLRX closed at $1.3199 (+111.15%) on 5,088,289 shares. The January 13, 2025 merger agreement with Decoy Therapeutics will create a public entity named Decoy Therapeutics, combining Salarius’s small-molecule degrader SP-3164 with Decoy’s IMP3ACT peptide platform. On April 16, 2025, MIT Professor Robert S. Langer joined the Scientific Advisory Board. Salarius filed an amended Form S-1 on June 16, and two Form 8-Ks on June 11 and June 16, 2025. Upcoming milestones include SP-3164’s IND submission, integration into PROTAC candidates, and interim data from seclidemstat Phase 1/2 trials.